pLM-fSV2A Citations (3)

Originally described in: Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells.
Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman FD, Studer L, Sadelain M Nat Biotechnol. 2011 Jan;29(1):73-8. doi: 10.1038/nbt.1717. Epub 2010 Dec 12. PubMed Journal

Articles Citing pLM-fSV2A

Articles
KLF4 N-terminal variance modulates induced reprogramming to pluripotency. Kim SI, Oceguera-Yanez F, Hirohata R, Linker S, Okita K, Yamada Y, Yamamoto T, Yamanaka S, Woltjen K. Stem Cell Reports. 2015 Apr 14;4(4):727-43. doi: 10.1016/j.stemcr.2015.02.004. Epub 2015 Mar 12. PubMed Associated Plasmids PB-TAC-OKMS PB-TAC-OSKM PB-TAC-OK+9MS PB-TAC-MKOS PB-TAC-EB-C5 More ...
Mesenchymal stem cells derived from human induced pluripotent stem cells retain adequate osteogenicity and chondrogenicity but less adipogenicity. Kang R, Zhou Y, Tan S, Zhou G, Aagaard L, Xie L, Bunger C, Bolund L, Luo Y. Stem Cell Res Ther. 2015 Aug 18;6:144. doi: 10.1186/s13287-015-0137-7. PubMed
PTBP1 acts as a dominant repressor of the aberrant tissue-specific splicing of ISCU in hereditary myopathy with lactic acidosis. Rawcliffe DFR, Osterman L, Nordin A, Holmberg M. Mol Genet Genomic Med. 2018 Nov;6(6):887-897. doi: 10.1002/mgg3.413. Epub 2018 Sep 12. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.